Articles tagged "Co-stimulation"

2016 American Transplant Congress
CD4 T Cell Mediated Help Is Required for Intra-Allograft Proliferation of Endogenous Memory CD8 T Cells and Their Ability to Mediate Rejection of Cardiac Allografts Subjected to Prolonged Ischemia.
H. Tsuda, T. Tanaka, C. Su, A. Valujskikh, R. Fairchild.
Immunology, Cleveland Clinic, Cleveland, OH.
Memory T cells are critical components to protective immunity against recurrent pathogens, but memory T cells with donor-reactivity pose a major barrier to successful transplantation…
2016 American Transplant Congress
Evaluating Posttransplant BKV-Specific T Cell Responses in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
M. McRae, T. How, A. Kirk, H. Xu.
Department of Surgery, Duke University, Durham, NC.
Belatacept-based maintenance regimens prevent acute allograft rejection following alemtuzumab induction, and patients so treated maintain intact anti-CMV and -EBV T cell immune responses without viral…
2016 American Transplant Congress
Combined CD122 and Costimulation Blockade Prolongs Allograft Survival by Controlling Expansion and Effector Function of Memory CD8 T Cells.
D. Mathews,¹ Y. Dong,¹ L. Higginbotham,¹ S. Kim,¹ C. Breeden,¹ J. Tso,² A. Adams.¹
¹Emory Transplant Center, Emory University, Atlanta, GA; ²JN Biosciences, Mountain View, CA.
CD8 memory T cells rely on signaling through CD122, the shared IL-2 and IL-15 receptor β-chain. The addition of anti-CD122 to costimulation blockade prolongs graft…
2016 American Transplant Congress
Investigating Posttransplant Allo-Donor Specific CD57⁺ Cells in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
H. Xu, F. Feng, A. Kirk.
Department of Surgery, Duke University, Durham, NC.
Recent studies have showed correlation between CD4+CD57+PD1- cells and costimulation blockade resistant rejection (CoBRR) in patients treated with belatacept without depletional induction. We have recently…
2016 American Transplant Congress
Absence of Host CD137 Signaling Converts Chronic GVHD Toward Acute GVHD.
H. Cho,^1,3 J. Lee,^1,4 J. Kim,¹ U. Moon,¹ B. Kwon,^1,2 S. Park,³ K. Park.⁴
¹Biomedical Research Center, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan, Republic of Korea; ²School of Biological Sciences, University of Ulsan, Ulsan, Republic of Korea; ³Department of Surgery, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan, Republic of Korea; ⁴Department of Internal Medicine, Ulsan University Hospital, School of Medicine, University of Ulsan, Ulsan, Republic of Korea.
CD137 functions mainly as a costimulatory molecule for T cell activation. However, its functions have been found in a variety of other immune and nonimmune…
2016 American Transplant Congress
Long-Lasting Skin Allograft Tolerance Induced and Maintained by Short-Term Vascularized Bone Marrow Transplant in a Mouse Model.
C.-H. Lin,¹ M. Anggelia,¹ H.-Y. Cheng,¹ Y.-L. Wang,¹ W.-Y. Chuang,¹ C.-H. Lin,¹ G. Brandacher.²
¹Center for Vascularized Composite Allotransplantation, Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan; ²Department of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD.
Background: Accumulating evidences indicate that vascularized bone marrow transplantation (VBMT) plays a critical role in inducing tolerance of vascularized composite allografts (VCA). Recipients with long-term…
2016 American Transplant Congress
A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.
A. Guasch,¹ H. Xu,² A. Mehta,¹ A. Ghali,¹ S. Mead,¹ H. Gebel,¹ R. Bray,¹ C. Larsen,¹ T. Pearson,¹ A. Kirk.²
¹Emory Transplant Center, Atlanta, GA; ²Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…
2016 American Transplant Congress
Tofacitinib Delivered by Solid Lipid Nanoparticles Inhibits Dendritic Cell Maturation and Their Allostimulatory Capacity.
J. Budihardjo,¹ M. Iglesias,¹ J. Walch,¹ X. Calderon-Colon,² W. Lee,¹ G. Brandacher,¹ J. Patrone,² G. Raimondi.¹
¹Plastic Surgery, Johns Hopkins Medical Institutions, Baltimore, MD; ²Applied Physics Laboratory, Johns Hopkins University, Laurel, MD.
BackgroundComplications caused by long-term immunosuppression remain a major concern for transplant patients. To optimize controlled and accurate dosing, we investigated an innovative drug delivery method…
2016 American Transplant Congress
Selective Deletion of Notch2 on B Cells Abrogates Alloantibody Production in Fully MHC-Mismatched Cardiac and Skin Transplant Models.
N. Murakami, C. Magee, T. Borges, J. Azzi, L. Riella.
Schuster Transplantation Research Center, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
Alloantibody-mediated injury remains a major challenge for the improvement of long-term graft survival and there is no effective therapy to prevent alloantibody generation post-transplant. The…
2016 American Transplant Congress
CD57+ CD4 T Cells Persist in the Periphery Following Kidney Transplantation.
J. Espinosa,^1,2 L. Stempora,¹ R. Townsend,³ A. Kirk.¹
¹Duke University, Durham; ²Emory University, Atlanta; ³Bristol-Meyers Squibb, Princeton.
Purpose: We have shown that CD57+PD1- CD4 T cells play a role in belatacept-resistant rejection, but their mechanism of action is incompletely defined. Potential mechanisms…